Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Poitiers University Hospital
With
Ministry of Health, France
Novartis
Study design Imatinib: starting at day -3: 600mg/day; continuous administration In combination with cytarabine: continuous iv/24h: 100mg/m² ; 7 days and daunorubicine: 4 levels
level 1: 0
level 2: 15mg/m² ; 3 days
level 3: 30mg/m² ; 3 days
level 4: 45mg/m² ; 3 days
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
CML Ph+ (assessed by cytogenetic or FISH)
Acute phase with ≥ 20% bone marrow blasts (M0 to M6 , excluding M3)
Age ≥ 18 year at inclusion
PS grade 0 to 2 (ECOG)
Adequate and organ function, defined as the following: total bilirubin \<1.5x uln, sgpt \<3x uln, creatinine \<1.5x uln.
Informed consent signed up
You may not be if
active malignancy other than CML or non-melanoma cancer of the skin
current treatment with another investigational agent
patients with grade 3/4 cardiac disease or any other serious concurrent medical condition.
patients who are pregnant or nursing. All patients of childbearing potential must practice effective methods of contraception while on study.
patients with mental illness or other condition precluding their ability to give informed consent or to comply with study requirements patients with performans status 3-4